This site contains materials related to Novo Nordisk scientific presentations at the Advanced Technologies & Treatments for Diabetes (ATTD) 2020 congress. The information on this site is intended for Healthcare Providers only and may relate to data concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. The information contained in this site is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product. Furthermore, it is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation.

The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have any questions regarding any information contained on this site you should consult a physician.

Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this website.

I have read and accept the legal notice for Novo Nordisk scientific presentations at ATTD 2020.

 Accept  Decline

Investigating the safety and glycaemic control of fast-acting insulin aspart with a closed-loop delivery system in adults with type 1 diabetes

SJ Russell,1 CA Balliro,2 M Ekelund,3 F El-Khatib,4 T Graungaard,5 R Jafri,1 N Rathor,6 J Sherwood,1 ER Damiano4

1Diabetes Research Unit, Massachusetts General Hospital, Boston, MA, USA; 2Biostatics Center, Massachusetts General Hospital, Boston, MA, USA; 3Type 1 Diabetes & Functional Insulins, Novo Nordisk A/S, Søborg, Denmark; 4Department of Biomedical Engineering, Boston University, Boston, MA, USA; 5Biostatistics, Novo Nordisk A/S, Søborg, Denmark; 6Medical Affairs, Novo Nordisk A/S, Søborg, Denmark


View Presentation


View Presentation

Share this Poster via Email


Presentation Slides

(1) Nimri et al. Am J Ther 2020;27:e30–e41;
(2) Pathak et al. Clin Med Insights Endocrinol Diab 2019;12:1–13;
(3) El-Khatib et al. J Clin Endocrinol Metab 2014;99:1701–11;
(4) Heise et al. Diab Obes Metab 2017;19:208–15;
(5) Dovc et al. Diab Care 2020;43:29–36.